Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030

Publication ID:

PB505240542

Publication Date:

May 15, 2024

Pages:

171

Publisher:

MRRPB5

Countries:

Global [1]

USD 5,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

A biomarker is, according to the US National Institutes of Health, 鈥渁 characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.鈥�
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
鈥� Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
鈥� Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
鈥� Proteomic biomarkers: Base on the analysis of the protein profiles.
鈥� Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).

Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications was estimated to be worth US$ 21390 million in 2023 and is forecast to a readjusted size of US$ 29810 million by 2030 with a CAGR of 4.8% during the forecast period 2024-2030.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
麻豆原创 Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in global and regional level.
Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 麻豆原创 by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size Estimates and Forecasts
2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size by Region: 2023 Versus 2030
2.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Region: 2019-2024
2.2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Region (2025-2030)
2.2.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue 麻豆原创 Share by Region (2019-2030)
3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Company
3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Company (2019-2024)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies around the World: Ranking by Revenue
3.3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Headquarters & Product Type
3.4.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Headquarters
3.4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Product & Service
3.4.3 Date of International Companies Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创
3.5 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Roche
4.1.1 Roche Company Information
4.1.2 Roche Description, Business Overview
4.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.1.5 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.1.6 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.1.7 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.1.8 Roche Recent Developments
4.2 Dako (Agilent Technologies)
4.2.1 Dako (Agilent Technologies) Company Information
4.2.2 Dako (Agilent Technologies) Description, Business Overview
4.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.2.5 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.2.6 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.2.7 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.2.8 Dako (Agilent Technologies) Recent Developments
4.3 Merck
4.3.1 Merck Company Information
4.3.2 Merck Description, Business Overview
4.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.3.5 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.3.6 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.3.7 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.3.8 Merck Recent Developments
4.4 BD
4.4.1 BD Company Information
4.4.2 BD Description, Business Overview
4.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.4.5 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.4.6 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.4.7 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.4.8 BD Recent Developments
4.5 Abbott
4.5.1 Abbott Company Information
4.5.2 Abbott Description, Business Overview
4.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.5.5 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.5.6 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.5.7 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.5.8 Abbott Recent Developments
4.6 Genesys Biolabs (20/20GeneSystems)
4.6.1 Genesys Biolabs (20/20GeneSystems) Company Information
4.6.2 Genesys Biolabs (20/20GeneSystems) Description, Business Overview
4.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.6.5 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.6.6 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.6.7 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.6.8 Genesys Biolabs (20/20GeneSystems) Recent Development
4.7 Affymetrix
4.7.1 Affymetrix Company Information
4.7.2 Affymetrix Description, Business Overview
4.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.7.5 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.7.6 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.7.7 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.7.8 Affymetrix Recent Development
4.8 Agendia
4.8.1 Agendia Company Information
4.8.2 Agendia Description, Business Overview
4.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.8.5 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.8.6 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.8.7 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.8.8 Agendia Recent Development
4.9 ALMAC
4.9.1 ALMAC Company Information
4.9.2 ALMAC Description, Business Overview
4.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.9.5 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.9.6 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.9.7 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.9.8 ALMAC Recent Development
4.10 Arrayit
4.10.1 Arrayit Company Information
4.10.2 Arrayit Description, Business Overview
4.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.10.5 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.10.6 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.10.7 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.10.8 Arrayit Recent Development
4.11 Biocartic
4.11.1 Biocartic Company Information
4.11.2 Biocartic Description, Business Overview
4.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.11.5 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.11.6 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.11.7 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.11.8 Biocartic Recent Development
4.12 BG Medicine
4.12.1 BG Medicine Company Information
4.12.2 BG Medicine Description, Business Overview
4.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.12.5 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.12.6 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.12.7 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.12.8 BG Medicine Recent Development
4.13 KEGG EXPRESSION Database
4.13.1 KEGG EXPRESSION Database Company Information
4.13.2 KEGG EXPRESSION Database Description, Business Overview
4.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.13.5 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.13.6 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.13.7 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.13.8 KEGG EXPRESSION Database Recent Development
4.14 Thermo Fisher
4.14.1 Thermo Fisher Company Information
4.14.2 Thermo Fisher Description, Business Overview
4.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.14.5 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.14.6 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.14.7 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.14.8 Thermo Fisher Recent Development
4.15 BGI
4.15.1 BGI Company Information
4.15.2 BGI Description, Business Overview
4.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products Offered
4.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue and Gross Margin (2019-2024)
4.15.5 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Product in 2023
4.15.6 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application in 2023
4.15.7 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Geographic Area in 2023
4.15.8 BGI Recent Development
5 Breakdown Data by Type
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2019-2024)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Type (2025-2030)
5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue 麻豆原创 Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2019-2024)
6.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Forecast by Application (2025-2030)
6.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue 麻豆原创 Share by Application (2019-2030)
7 North America
7.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size YoY Growth 2019-2030
7.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Facts & Figures by Country (2019-2030)
7.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2019-2024)
7.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size YoY Growth 2019-2030
8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2019-2024)
8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2019-2024)
9 Europe
9.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size YoY Growth 2019-2030
9.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Facts & Figures by Country (2019-2030)
9.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2019-2024)
9.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size YoY Growth 2019-2030
10.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Facts & Figures by Country (2019-2030)
10.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2019-2024)
10.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Size YoY Growth 2019-2030
11.2 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Type (2019-2024)
11.4 Middle East and Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Supply Chain Analysis
12.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Raw Materials and Upstream Suppliers
12.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Clients Analysis
12.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Channel and Sales Model Analysis
12.4.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distributors
13 麻豆原创 Dynamics
13.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
13.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Drivers
13.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Challenges
13.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.